Low Levels of IgM Antibodies against an Advanced Glycation Endproduct–Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects
Low Levels of IgM Antibodies against an Advanced Glycation Endproduct–Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started